Glenn W. Welling
Engaged Capital
Glenn W. Welling Anika Therapeutics Inc stake
total: 101
Engaged Capital ANIK trades
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 1
- Held since:
- 2018 Q2
- Held for:
- 3 quarters
- Latest activity:
- 2019 Q1
According to 2026 Q2 report, Glenn W. Welling doesn't hold any Anika Therapeutics Inc (ANIK) shares. To date, the estimated cost basis is nearly $35.27 for "buy" trades and estimated average "sell" price is $33.61. Engaged Capital first purchased ANIK in 2018 Q2, initially acquiring 262,547 shares. Since the initial investment in Anika Therapeutics Inc (ANIK), Engaged Capital has made 3 more transactions.
When did Glenn W. Welling sell Anika Therapeutics Inc (ANIK)?
Glenn W. Welling sold off the entire Anika Therapeutics Inc (ANIK) position in 2019 Q1.
When did Glenn W. Welling buy Anika Therapeutics Inc (ANIK)?
Glenn W. Welling first invested in Anika Therapeutics Inc (ANIK) in 2018 Q2 at the reported quarter-end price of $32.00 per share.
What's the cost basis of Engaged Capital's ANIK stake?
The estimated cost basis for Anika Therapeutics Inc (ANIK) stake is around $35.27 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $35.27
- Weighted AVG sell price:
- $33.61
Glenn W. Welling's historical trades in Anika Therapeutics Inc
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2019 Q1
|
0.00%
|
$33.61
|
-100% (-374,926)
|
|||
|
2018 Q4
|
2.34%
|
$33.61
|
-3.10% (-12,000)
|
|||
|
2018 Q3
|
2.29%
|
$42.18
|
+47.37% (+124,379)
|
|||
|
2018 Q2
|
1.06%
|
$32.00
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.